Iceland's Public Supports Database, But Scientists Object

On Dec. 17, 1998, Iceland's parliament, the Althing, gave the go-ahead for a Delaware-based biotechnology company, deCODE Genetics Inc., to use existing health and genealogy records to establish a nationwide "health sector database ... with the aim of increasing knowledge in order to improve health and health services."1 The public's participation was presumed--citizens were given six months to "opt out" of the plan. By June 17, 1999, with only about 9,000 of the country's 270,000 residents of

Written byRicki Lewis
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

On Dec. 17, 1998, Iceland's parliament, the Althing, gave the go-ahead for a Delaware-based biotechnology company, deCODE Genetics Inc., to use existing health and genealogy records to establish a nationwide "health sector database ... with the aim of increasing knowledge in order to improve health and health services."1 The public's participation was presumed--citizens were given six months to "opt out" of the plan.

By June 17, 1999, with only about 9,000 of the country's 270,000 residents officially opted out, it was clear that the public had agreed to take part--or, put more accurately, had failed to disagree. This came as no surprise. "The polls have shown 88 percent of the population supports the database. I've been on the road a long time, and have talked to everyone, and there's almost universal support," says Kari Stefansson, founder and CEO of deCODE.

But despite what seems like a successful maneuver on the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies